Clinical trials: Cancer Refractory
Acute Myeloid Leukemia, Lymphoid Leukemia
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
The study will be a prospective open-label single-center study in previously treated patients with Acute Myeloid Leukemia (AML) or Acute Lymphoid Leukemia (ALL).
- Trial name
- NCT02462265
- Testing
- Oshadi D & Oshadi R;, salvage therapy cytosar and mitoxantrone
- Volunteers
- 15 people
- Sponsor
- Oshadi Drug Administration
Small Cell Lung Cancer (SCLC)
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on survival, how much time may pass without disease…
- Trial name
- NCT01904253
- Testing
- TAS-102, Amrubicin (Japan), Topotecan (Japan/Europe)
- Where
- 23 sites in Germany, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT07336472
- Testing
- IBI3003
- Where
- 6 sites in United States
- Volunteers
- 360 people
- Sponsor
- Fortvita Biologics (USA)Inc.
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Differentiated Thyroid Carcinoma, Medullary Thyroid Carcinoma
Spanish Study for Molecular Characterization of Thyroid Carcinoma
This project is a retrospective observational study based on the molecular characterization of a Spanish population of patients with refractory radio-iodine differentiated thyroid cancer (DTC) and medullary thyroid carcinoma…
- Trial name
- MOLTHY (NCT04970134)
- Testing
- Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Oncomine Focus Assay Platform with 52 genes
- Where
- 12 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT06723457
- Testing
- Biospecimen Collection, Computed Tomography, Epcoritamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Reem Karmali
B-cell Malignancy
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).
- Trial name
- NCT05106907
- Testing
- ThisCART19 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fundamenta Therapeutics, Ltd.
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
This phase II trial studies how well nab-paclitaxel and alpelisib works in treating patients with triple negative breast cancer with PIK3CA or PTEN alterations that does not respond to anthracycline chemotherapy (anthrocycline…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04216472
- Testing
- Alpelisib, Nab-paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
The purpose of this research study is to test the safety, tolerability, and effectiveness of two chemotherapy drugs, pegylated liposomal doxorubicin (Doxil) and bevacizumab (Avastin).
- Trial name
- NCT00945139
- Testing
- Doxil, Avastin
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- New Mexico Cancer Research Alliance
Multiple Myeloma
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine if there is an improvement in progression-free survival (length of time during and after treatment in which a patient is living with a disease that does not get worse) when siltuximab is…
- Trial name
- NCT01266811
- Testing
- Siltuximab, Velcade and dexamethasone
- Where
- 48 sites in United States, Australia and 12 more
- Sponsor
- Centocor, Inc.
Leukemia
Clofarabine Bone Marrow Cytoreduction
For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT.
- Trial name
- NCT00724009
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Chicago
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib after an autologous peripheral blood stem cell transplant may stop the growth of any cancer cells…
- Trial name
- NCT00288028
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hodgkin Lymphoma
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth).
- Trial name
- NCT05508867
- Testing
- favezelimab/pembrolizumab, bendamustine, gemcitabine
- Where
- 105 sites in United States, Argentina and 18 more
- Volunteers
- 203 people
- Sponsor
- Merck Sharp & Dohme LLC
Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer.
- Conditions
- Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma
- Trial name
- NCT06566092
- Testing
- LN-145/LN-144
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Iovance Biotherapeutics, Inc.
B-All, Acute Lymphoblastic Leukemia
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Background: B-cell acute lymphoblastic leukemia (B-ALL) is a type of blood cancer. Some people with B-ALL have a gene mutation that makes the disease hard to treat.
- Trial name
- NCT07572136
- Testing
- TSLPR-CART, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Multiple Myeloma
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT03309111
- Testing
- ISB 1342
- Where
- 20 sites in United States, France
- Volunteers
- 81 people
- Sponsor
- Ichnos Sciences SA
Multiple Myeloma
Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib
Clinical trial with a pharmaceutical specialty in a new combination. Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with multiple treatment-resistant or relapsing myeloma who have…
- Trial name
- POCODEX (NCT04243109)
- Testing
- Pomalidomide + Cyclophosphamide + Dexamethasone
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Acute Myeloid Leukemia
QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia
NK cells from patients with malignant diseases are often functionally impaired. Their function cannot be fully restored through ex vivo expansion and cytokine activation.
- Trial name
- NCT00900809
- Testing
- Neukoplast™ (NK-92)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- ImmunityBio, Inc.
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Trial name
- NCT02879695
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed or refractory low-grade non-Hodgkin's lymphoma.
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT00022581
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.